<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b7e16f4a-4494-4311-a947-c30f64684726"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>CEFDINIR CAPSULES, USP<br/> 300 mg<br/>  Rx only<br/>  To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.<br/>
   </title>
   <effectiveTime value="20250407"/>
   <setId root="d5fd32d8-66de-4a9f-9b83-88b190a90377"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
            <name>Bryant Ranch Prepack</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                  <name>Bryant Ranch Prepack</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                        <name>Bryant Ranch Prepack</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="63629-5101"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RELABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="63629-5101"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="8b54c96f-b31d-42db-a6b1-a9ed68a131a6"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20210223"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63629-5101" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefdinir</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefdinir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="67877-543" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="300" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="CI0FAO63WC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFDINIR</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CI0FAO63WC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFDINIR</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="UTY7PDF93L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOXYMETHYLCELLULOSE CALCIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="13A4J4NH9I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYOXYL 40 STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63629-5101-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250407"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA210220" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20210220"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE">
                              <originalText>Blue opaque cap</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE">
                              <originalText>Blue opaque body</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="22"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A041;300</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <observationMedia ID="MM1">
                     <text>cefdinir-structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="cefdinir-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="a71c94d1-6db3-47df-a976-77202bf22bd5"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Cefdinir capsules, USP contain the active ingredient cefdinir, an extended-spectrum, semisynthetic cephalosporin, for oral administration. Chemically, cefdinir is [6R-[6α,7β (Z)]]-7-[[(2-amino-4  thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid. Cefdinir is a white to slightly brownish-yellow solid. It is slightly soluble in dilute hydrochloric acid and sparingly soluble in 0.1 M pH 7.0 phosphate buffer.The empirical formula is C<sub>14</sub>H<sub>13</sub>N<sub>5</sub>O<sub>5</sub>S<sub>2</sub> and the molecular weight is 395.42. Cefdinir has the structural formula shown below:<br/>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Cefdinir capsules, USP contain 300 mg cefdinir and the following inactive ingredients:</paragraph>
                  <paragraph>carboxymethylcellulose calcium, polyoxyl 40 stearate, colloidal silicone dioxide and magnesium stearate.</paragraph>
                  <paragraph>The capsule shells contain FD&amp;C Blue #2; gelatin, titanium dioxide, gelatin and water. Imprinting ink components shellac, Black Iron Oxide and potassium hydroxide.</paragraph>
               </text>
               <effectiveTime value="20220628"/>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="77f05165-6c04-493a-b7e9-1ed722a6ac6e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20220628"/>
               <component>
                  <section ID="Section_2.1">
                     <id root="41de2cd0-78fd-4601-9549-cfe1802c9f49"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>Pharmacokinetics and Drug Metabolism</title>
                     <text>
                        <paragraph>Absorption</paragraph>
                        <paragraph>
                           <content styleCode="italics">Oral Bioavailability</content>
                        </paragraph>
                        <br/>
                        <paragraph>Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Plasma cefdinir concentrations increase with dose, but the increases are less than dose-proportional from 300 mg (7 mg/kg) to 600 mg (14 mg/kg). Following administration of suspension to healthy adults, cefdinir bioavailability is 120% relative to capsules. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%.<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                           <br/>
                           <br/>
                        </paragraph>
                        <paragraph>The C<sub>max</sub> and AUC of cefdinir from the capsules are reduced by 16% and 10%, respectively, when given with a high-fat meal. In adults given the 250 mg/5 mL oral suspension with a high-fat meal, the C<sub>max</sub> and AUC of cefdinir are reduced by 44% and 33%, respectively. The magnitude of these reductions is not likely to be clinically significant. Therefore, cefdinir may be taken without regard to food.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Cefdinir Capsules</content>
                           <br/>
                           <br/>
                        </paragraph>
                        <paragraph>Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 300 and 600 mg oral doses of cefdinir to adult subjects are presented in the following table:</paragraph>
                        <br/>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Mean (±SD) Plasma Cefdinir </content>
                           <content styleCode="bold">Pharmacokinetic Parameter Values </content>Following Administration of Capsules to Adult Subjects</paragraph>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0">
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="justify" valign="middle">
                                    <content styleCode="bold"/>
                                    <br/>
                                    <content styleCode="bold"> Dose</content>
                                 </td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>
                                    </content>
                                    <content styleCode="bold">(mcg /mL)</content>
                                 </td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <content styleCode="bold"/>
                                    <br/>
                                    <content styleCode="bold"> t</content>
                                    <content styleCode="bold">
                                       <sub>max</sub>(hr)</content>
                                 </td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>
                                    <content styleCode="bold">AUC(mcg•hr/mL)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="justify" valign="middle">
                                    <br/>300 mg</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>1.60</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>2.9</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>7.05</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="justify" valign="middle">
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>(0.55)</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>(0.89)</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>(2.17)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="justify" valign="middle">
                                    <br/>600 mg</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>2.87</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>3.0</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>11.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="justify" valign="middle">
                                    <br/>
                                 </td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>(1.01)</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>(0.66)</td>
                                 <td styleCode="Rrule" align="justify" valign="middle">
                                    <br/>(3.87)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Multiple Dosing</content>
                        </paragraph>
                        <br/>
                        <paragraph>Cefdinir does not accumulate in plasma following once- or twice-daily administration to subjects with normal renal function.<br/>
                           <br/>
                        </paragraph>
                        <paragraph>Distribution<br/>
                           <br/>
                        </paragraph>
                        <paragraph>The mean volume of distribution (Vd<sub>area</sub> ) of cefdinir in adult subjects is 0.35 L/kg (±0.29); in pediatric subjects (age 6 months to 12 years), cefdinir Vd<sub>area</sub> is 0.67 L/kg (±0.38). Cefdinir is 60% to 70% bound to plasma proteins in both adult and pediatric subjects; binding is independent of concentration.<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin Blister</content>
                           <br/>
                           <br/>
                        </paragraph>
                        <paragraph>In adult subjects, median (range) maximal blister fluid cefdinir concentrations of 0.65 (0.33 to 1.1) and 1.1 (0.49 to 1.9) mcg/mL were observed 4 to 5 hours following administration of 300 and 600 mg doses, respectively. Mean (±SD) blister C<sub>max</sub> and AUC (0-∞) values were 48% (±13) and 91% (±18) of corresponding plasma values.<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Tonsil Tissue<br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>In adult patients undergoing elective tonsillectomy, respective median tonsil tissue cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were 0.25 (0.22 to 0.46) and 0.36 (0.22 to 0.80) mcg/g. Mean tonsil tissue concentrations were 24% (±8) of corresponding plasma concentrations.<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Sinus Tissue<br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>In adult patients undergoing elective maxillary and ethmoid sinus surgery, respective median sinus tissue cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were &lt; 0.12 (&lt; 0.12 to 0.46) and 0.21 (&lt; 0.12 to 2.0) mcg/g. Mean sinus tissue concentrations were 16% (±20) of corresponding plasma concentrations.<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Lung Tissue<br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>In adult patients undergoing diagnostic bronchoscopy, respective median bronchial mucosa cefdinir concentrations 4 hours after administration of single 300 and 600 mg doses were 0.78 (&lt; 0.06 to 1.33) and 1.14 (&lt; 0.06 to 1.92) mcg/mL, and were 31% (±18) of corresponding plasma concentrations. Respective median epithelial lining fluid concentrations were 0.29 (&lt; 0.3 to 4.73) and 0.49 (&lt; 0.3 to 0.59) mcg/mL, and were 35% (±83) of corresponding plasma concentrations.<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Middle Ear Fluid</content>
                           <br/>
                           <br/>
                        </paragraph>
                        <paragraph>In 14 pediatric patients with acute bacterial otitis media, respective median middle ear fluid cefdinir concentrations 3 hours after administration of single 7 and 14 mg/kg doses were 0.21 (&lt; 0.09 to 0.94) and 0.72 (0.14 to 1.42) mcg/mL. Mean middle ear fluid concentrations were 15% (±15) of corresponding plasma concentrations.<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">CSF<br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>Data on cefdinir penetration into human cerebrospinal fluid are not available.<br/>
                           <br/>
                        </paragraph>
                        <paragraph>Metabolism and Excretion<br/>
                           <br/>
                        </paragraph>
                        <paragraph>Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t<sub>1/2</sub> ) of 1.7 (±0.6) hours. In healthy subjects with normal renal function, renal clearance is 2.0 (±1.0) mL/min/kg, and apparent oral clearance is 11.6 (±6.0) and 15.5 (±5.4) mL/min/kg following doses of 300 and 600 mg, respectively. Mean percent of dose recovered unchanged in the urine following 300 and 600 mg doses is 18.4% (±6.4) and 11.6% (±4.6), respectively. Cefdinir clearance is reduced in patients with renal dysfunction (see <content styleCode="bold">
                              <content styleCode="italics">Special Populations:</content>
                           </content> Patients with Renal Insufficiency).<br/>
                           <br/>
                        </paragraph>
                        <paragraph>Because renal excretion is the predominant pathway of elimination, dosage should be adjusted in patients with markedly compromised renal function or who are undergoing hemodialysis (see <content styleCode="bold">
                              <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>).<br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>Special Populations<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Insufficiency<br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>Cefdinir pharmacokinetics were investigated in 21 adult subjects with varying degrees of renal function. Decreases in cefdinir elimination rate, apparent oral clearance (CL/F), and renal clearance were approximately proportional to the reduction in creatinine clearance (CL<sub>cr</sub> ). As a result, plasma cefdinir concentrations were higher and persisted longer in subjects with renal impairment than in those without renal impairment. In subjects with CL<sub>cr</sub> between 30 and 60 mL/min, C<sub>max</sub> and t<sub>1/2</sub> increased by approximately 2-fold and AUC by approximately 3-fold. In subjects with CL<sub>cr</sub>&lt;30 mL/min, C<sub>max</sub> increased by approximately 2-fold, t<sub>1/2</sub> by approximately 5-fold, and AUC by approximately 6-fold. Dosage adjustment is recommended in patients with markedly compromised renal function (creatinine clearance &lt;30 mL/min; see <content styleCode="bold">
                              <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>).<br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hemodialysis</content>
                           <br/>
                           <br/>
                        </paragraph>
                        <paragraph>Cefdinir pharmacokinetics were studied in 8 adult subjects undergoing hemodialysis. Dialysis (4 hours duration) removed 63% of cefdinir from the body and reduced apparent elimination t<sub>1/2</sub> from 16 (±3.5) to 3.2 (±1.2) hours. Dosage adjustment is recommended in this patient population (see <content styleCode="bold">
                              <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>).</content>
                           <br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Disease<br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>Because cefdinir is predominantly renally eliminated and not appreciably metabolized, studies in patients with hepatic impairment were not conducted. It is not expected that dosage adjustment will be required in this population.<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatric Patients<br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>The effect of age on cefdinir pharmacokinetics after a single 300 mg dose was evaluated in 32 subjects 19 to 91 years of age. Systemic exposure to cefdinir was substantially increased in older subjects (N=16), C<sub>max</sub> by 44% and AUC by 86%. This increase was due to a reduction in cefdinir clearance. The apparent volume of distribution was also reduced, thus no appreciable alterations in apparent elimination t<sub>1/2</sub> were observed (elderly: 2.2 ± 0.6 hours vs young: 1.8 ± 0.4 hours). Since cefdinir clearance has been shown to be primarily related to changes in renal function rather than age, elderly patients do not require dosage adjustment unless they have markedly compromised renal function (creatinine clearance &lt; 30 mL/min, see <content styleCode="italics">Patients with Renal Insufficiency</content>, above).<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gender and Race<br/>
                              <br/>
                           </content>
                        </paragraph>
                        <paragraph>The results of a meta-analysis of clinical pharmacokinetics (N=217) indicated no significant impact of either gender or race on cefdinir pharmacokinetics.</paragraph>
                     </text>
                     <effectiveTime value="20231215"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="23c83904-b4b8-4311-b721-5b9b1d9a4e30"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>Microbiology</title>
                     <text>
                        <paragraph>Mechanism of Action</paragraph>
                        <br/>
                        <paragraph>As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, β-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.</paragraph>
                        <br/>
                        <paragraph>Mechanism of Resistance</paragraph>
                        <br/>
                        <paragraph>Resistance to cefdinir is primarily through hydrolysis by some β-lactamases, alteration of penicillinbinding proteins (PBPs) and decreased permeability. Cefdinir is inactive against most strains of <content styleCode="italics">Enterobacter </content>spp., <content styleCode="italics">Pseudomonas </content>spp., <content styleCode="italics">Enterococcus </content>spp., penicillin-resistant streptococci, and methicillin-resistant staphylococci. β-lactamase negative, ampicillin-resistant (BLNAR) <content styleCode="italics">H. influenza </content>strains are typically non-susceptible to cefdinir. </paragraph>
                        <br/>
                        <paragraph>Antimicrobial Activity</paragraph>
                        <br/>
                        <paragraph>Cefdinir has been shown to be active against most strains of the following microorganisms, both <content styleCode="italics">in vitro </content>and in clinical infections as described in <content styleCode="bold">
                              <linkHtml href="#Section_3">INDICATIONS AND USAGE</linkHtml>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Gram-Po</content>
                           <content styleCode="underline">sitive Bacteria</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus aureus </content>(methicillin-susceptible strains only) <content styleCode="italics">Streptococcus pneumoniae </content>(penicillin-susceptible strains only) <content styleCode="italics">Streptococcus pyogenes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Gram-Neg</content>
                           <content styleCode="underline">ative Bacteria </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Haemophilus influenzae </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Haemophilus parainfluenza</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Moraxella catarrhalis</content>
                        </paragraph>
                        <br/>
                        <paragraph>The following in vitro data are available, but their clinical significance is unknown.</paragraph>
                        <br/>
                        <paragraph>Cefdinir exhibits <content styleCode="italics">in vitro</content> minimum inhibitory concentrations (MICs) of 1 mcg/mL or less against (≥ 90%) strains of the following    microorganisms; however, the safety and effectiveness of cefdinir in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Gram-Po</content>
                           <content styleCode="underline">sitive Bacteria</content>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus epidermidis </content>(methicillin-susceptible strains only) </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Streptococcus agalactiae</content>
                        </paragraph>
                        <br/>
                        <paragraph> Viridans group streptococci</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Gram-Neg</content>
                           <content styleCode="underline">ative Bacteria </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Citrobacter koseri </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Escherichia coli</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Klebsiella pneumoniae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"> Proteus mirabilis<br/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline"> Susceptibility Testing </content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                     </text>
                     <effectiveTime value="20231215"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="17fd7849-251e-447f-bf72-8bb6066838bb"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS &amp; USAGE</title>
               <text>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                  <br/>
                  <paragraph>Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Adults and Adolescents</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>Community-Acquired Pneumonia </paragraph>
                  <br/>
                  <paragraph>Caused by <content styleCode="italics">Haemophilus influenzae </content>(including β-lactamase producing strains), <content styleCode="italics">Haemophilus parainfluenzae </content>(including β-lactamase producing strains), <content styleCode="italics">Streptococcus pneumoniae </content>(penicillin-susceptible strains only), and <content styleCode="italics">Moraxella catarrhalis </content>(including β-lactamase producing strains) (see <content styleCode="bold">
                        <linkHtml href="#Section_13">CLINICAL STUDIES</linkHtml>
                     </content>).</paragraph>
                  <br/>
                  <paragraph>Acute Exacerbations of Chronic Bronchitis</paragraph>
                  <br/>
                  <paragraph>Caused by <content styleCode="italics">Haemophilus influenzae </content>(including β-lactamase producing strains), <content styleCode="italics">Haemophilus parainfluenzae </content>(including β-lactamase producing strains), <content styleCode="italics">Streptococcus pneumoniae </content>(penicillin-susceptible strains only), and <content styleCode="italics">Moraxella catarrhalis </content>(including β-lactamase producing strains).</paragraph>
                  <br/>
                  <paragraph>Acute Maxillary Sinusitis</paragraph>
                  <br/>
                  <paragraph>Caused by <content styleCode="italics">Haemophilus influenzae </content>(including β-lactamase producing strains), <content styleCode="italics">Streptococcus pneumoniae </content>(penicillin-susceptible strains only), and <content styleCode="italics">Moraxella catarrhalis </content>(including β-lactamase producing strains).</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">NOTE: </content>For information on use in pediatric patients, see <content styleCode="bold">
                        <linkHtml href="#Section_6.10">Pediatric Use</linkHtml>
                     </content>and <content styleCode="bold">
                        <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                     </content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>Pharyngitis/Tonsillitis</paragraph>
                  <br/>
                  <paragraph>Caused by <content styleCode="bold">
                        <content styleCode="italics">Streptococcus pyogenes </content>
                     </content>(see <content styleCode="bold">CLINICAL STUDIES</content>).</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">NOTE: </content>Cefdinir is effective in the eradication of <content styleCode="italics">S. pyogenes </content>from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following <content styleCode="italics">S. pyogenes </content>pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.</paragraph>
                  <br/>
                  <paragraph>Uncomplicated Skin and Skin Structure Infections</paragraph>
                  <paragraph>Caused by <content styleCode="italics">Staphylococcus aureus </content>(including β-lactamase producing strains) and <content styleCode="italics">Streptococcus pyogenes</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Pediatric Patients</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>Acute Bacterial Otitis Media</paragraph>
                  <br/>
                  <paragraph>Caused by <content styleCode="italics">Haemophilus influenzae </content>(including β-lactamase producing strains), <content styleCode="italics">Streptococcus pneumoniae </content>(penicillin-susceptible strains only), and <content styleCode="italics">Moraxella catarrhalis </content>(including β-lactamase producing strains).</paragraph>
                  <br/>
                  <paragraph>Pharyngitis/Tonsillitis</paragraph>
                  <br/>
                  <paragraph>Caused by <content styleCode="italics">Streptococcus pyogenes </content>(see <content styleCode="bold">
                        <linkHtml href="#Section_13">CLINICAL STUDIES</linkHtml>
                     </content>).</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NOTE: </content>Cefdinir is effective in the eradication of <content styleCode="italics">S. pyogenes </content>from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following <content styleCode="italics">S. pyogenes </content>pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.</paragraph>
                  <br/>
                  <paragraph>Uncomplicated Skin and Skin Structure Infections</paragraph>
                  <br/>
                  <paragraph>Caused by <content styleCode="italics">Staphylococcus aureus </content>(including β-lactamase producing strains) and <content styleCode="italics">Streptococcus pyogenes</content>.</paragraph>
               </text>
               <effectiveTime value="20220628"/>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="209a0e58-6a9f-4d4c-856c-5edc9b2ae532"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Cefdinir is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.</paragraph>
               </text>
               <effectiveTime value="20220628"/>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="956dccb8-4b09-4ef9-abd3-746ad424d6fb"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">BEFORE THERAPY WITH CEFDINIR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFDINIR, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFDINIR IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFDINIR OCCURS, THE DRUG SHOULD BE DISCONTINUED. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Clostridium difficile </content>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefdinir, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="italics">C. difficile </content>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile </content>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                  <br/>
                  <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile </content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
               </text>
               <effectiveTime value="20231215"/>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="ffe5361c-f142-4fbe-ab9e-bd4648fde0f3"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20220628"/>
               <component>
                  <section ID="Section_6.1">
                     <id root="1913c705-3ee0-4508-bdd2-1e85aed307cf"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>GENERAL</title>
                     <text>
                        <paragraph>Prescribing cefdinir in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                        <br/>
                        <paragraph>As with other broad-spectrum antibiotics, prolonged treatment may result in the possible emergence and overgrowth of resistant organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate alternative therapy should be administered.</paragraph>
                        <br/>
                        <paragraph>Cefdinir, as with other broad-spectrum antimicrobials (antibiotics), should be prescribed with caution in individuals with a history of colitis.</paragraph>
                        <br/>
                        <paragraph>In patients with transient or persistent renal insufficiency (creatinine clearance &lt; 30 mL/min), the total daily dose of cefdinir should be reduced because high and prolonged plasma concentrations of cefdinir can result following recommended doses (see <content styleCode="bold">
                              <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20231215"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="12ea2f7d-0e0a-4545-bdc9-c2ed87d75d34"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>INFORMATION FOR PATIENTS</title>
                     <text>
                        <br/>
                        <paragraph>Patients should be counseled that antibacterial drugs including cefdinir should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefdinir is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefdinir or other antibacterial drugs in the future.</paragraph>
                        <br/>
                        <paragraph>Antacids containing magnesium or aluminum interfere with the absorption of cefdinir. If this type of antacid is required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the antacid.</paragraph>
                        <br/>
                        <paragraph>Iron supplements, including multivitamins that contain iron, interfere with the absorption of cefdinir. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement.</paragraph>
                        <br/>
                        <paragraph>Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20231215"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.4">
                     <id root="2002f054-0a65-46d5-bb86-a5d6f00a51c1"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>DRUG INTERACTIONS</title>
                     <text>
                        <paragraph>Antacids (Aluminum- or Magnesium-Containing)</paragraph>
                        <br/>
                        <paragraph>Concomitant administration of 300 mg cefdinir capsules with 30 mL Maalox<sup>®</sup> TC suspension reduces the rate (C<sub>max</sub>) and extent (AUC) of absorption by approximately 40%. Time to reach C<sub>max</sub> is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If antacids are required during cefdinir capsule therapy, cefdinir should be taken at least 2 hours before or after the antacid.</paragraph>
                        <br/>
                        <paragraph>Probenecid</paragraph>
                        <br/>
                        <paragraph>As with other β-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in AUC, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination t<sub>1/2</sub> .</paragraph>
                        <br/>
                        <paragraph>Iron Supplements and Foods Fortified With Iron</paragraph>
                        <br/>
                        <paragraph>Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO<sub>4</sub> ) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement.</paragraph>
                        <br/>
                        <paragraph>The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.</paragraph>
                        <br/>
                        <paragraph>There have been reports of reddish stools in patients receiving cefdinir. In many cases, patients were also receiving iron-containing products. The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.</paragraph>
                     </text>
                     <effectiveTime value="20231215"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.5">
                     <id root="4bd9f119-99ee-43bd-bc72-26afe48c4e51"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>DRUG &amp; OR LABORATORY TEST INTERACTIONS</title>
                     <text>
                        <paragraph>A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest®, Benedict’s solution, or Fehling’s solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix® or Tes-Tape®) be used. Cephalosporins are known to occasionally induce a positive direct Coombs’ test.</paragraph>
                     </text>
                     <effectiveTime value="20220628"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.6">
                     <id root="67cf3eed-2aff-4ea2-864c-da6270c897a3"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY</title>
                     <text>
                        <paragraph>The carcinogenic potential of cefdinir has not been evaluated. No mutagenic effects were seen in the bacterial reverse mutation assay (Ames) or point mutation assay at the hypoxanthine-guanine phosphoribosyltransferase locus (HGPRT) in V79 Chinese hamster lung cells. No clastogenic effects were observed <content styleCode="italics">in vitro</content> in the structural chromosome aberration assay in V79 Chinese hamster lung cells or <content styleCode="italics">in vivo </content>in the micronucleus assay in mouse bone marrow. In rats, fertility and reproductive performance were not affected by cefdinir at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m<sup>2</sup> /day).</paragraph>
                     </text>
                     <effectiveTime value="20220628"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.7">
                     <id root="b0b2c4b8-256c-4d43-80c6-1a09f1df5437"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>PREGNANCY</title>
                     <text>
                        <paragraph>Teratogenic Effects</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Pregnancy Category B</content>
                        </paragraph>
                        <br/>
                        <paragraph>Cefdinir was not teratogenic in rats at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m<sup>2</sup> /day) or in rabbits at oral doses up to 10 mg/kg/day (0.7 times the human dose based on mg/kg/day, 0.23 times based on mg/m<sup>2</sup> /day). Maternal toxicity (decreased body weight gain) was observed in rabbits at the maximum tolerated dose of 10 mg/kg/day without adverse effects on offspring. Decreased body weight occurred in rat fetuses at ≥ 100 mg/kg/day, and in rat offspring at ≥ 32 mg/kg/day. No effects were observed on maternal reproductive parameters or offspring survival, development, behavior, or reproductive function.</paragraph>
                        <br/>
                        <paragraph>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20220628"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.8">
                     <id root="e8b88fb9-4e52-490b-bd53-993560498465"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>LABOR &amp; DELIVERY</title>
                     <text>
                        <paragraph>Cefdinir has not been studied for use during labor and delivery.</paragraph>
                     </text>
                     <effectiveTime value="20220628"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.9">
                     <id root="7484dab4-64f8-4d89-b6be-0e9d8a9760e1"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>NURSING MOTHERS</title>
                     <text>
                        <paragraph>Following administration of single 600 mg doses, cefdinir was not detected in human breast milk.</paragraph>
                     </text>
                     <effectiveTime value="20220628"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.10">
                     <id root="39cd063c-cae5-4d8a-9594-286a53d4a587"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>PEDIATRIC USE</title>
                     <text>
                        <paragraph>Safety and efficacy in neonates and infants less than 6 months of age have not been established. Use of cefdinir for the treatment of acute maxillary sinusitis in pediatric patients (age 6 months through 12 years) is supported by evidence from adequate and well-controlled studies in adults and adolescents, the similar pathophysiology of acute sinusitis in adult and pediatric patients, and comparative pharmacokinetic data in the pediatric population.</paragraph>
                     </text>
                     <effectiveTime value="20220628"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.11">
                     <id root="a0624e9d-6ad2-4079-8d4b-eb2211ffd8bf"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>GERIATRIC USE</title>
                     <text>
                        <paragraph>Efficacy is comparable in geriatric patients and younger adults. While cefdinir has been well-tolerated in all age groups, in clinical trials geriatric patients experienced a lower rate of adverse events, including diarrhea, than younger adults. Dose adjustment in elderly patients is not necessary unless renal function is markedly compromised (see <content styleCode="bold">
                              <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20220628"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="427640be-8d8d-4c38-9e2f-f78038f16caa"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE EVENTS</title>
               <text>
                  <paragraph>Clinical Trials</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="italics">Cefdinir Capsules (Adult and Adolescent Patients)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics"/>
                  </paragraph>
                  <paragraph>In clinical trials, 5093 adult and adolescent patients (3841 U.S. and 1252 non-U.S.) were treated with the recommended dose of cefdinir capsules (600 mg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. One hundred forty-seven of 5093 (3%) patients discontinued medication due to adverse events thought by the investigators to be possibly, probably, or definitely associated with cefdinir therapy. The discontinuations were primarily for gastrointestinal disturbances, usually diarrhea or nausea. Nineteen of 5093 (0.4%) patients were discontinued due to rash thought related to cefdinir administration.</paragraph>
                  <br/>
                  <paragraph>In the U.S., the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir capsules in multiple-dose clinical trials (N=3841 cefdinir-treated patients):</paragraph>
                  <paragraph>
                     <content styleCode="bold">Adverse Events Associated with Cefdinir Capsules U.S. Trials in Adult and Adolescent Patients (N=3841)*</content>
                  </paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" width="495.8905">
                     <colgroup>
                        <col width="28.5235349336194%"/>
                        <col width="36.5562558669706%"/>
                        <col width="34.9202091994099%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="6" valign="top">Incidence ≥1%<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Diarrhea<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">15% <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Vaginal moniliasis<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">4% of women<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Nausea<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">3%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Headache<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Abdominal pain<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">1%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Vaginitis<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">1% of women<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="15" valign="top">Incidence &lt; 1%<br/>but &gt; 0.1%<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Rash<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.9%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Dyspepsia<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.7%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Flatulence<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.7%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Vomiting<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.7%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Abnormal stools<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.3%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Anorexia<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.3%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Constipation<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.3%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Dizziness<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.3%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Dry mouth<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.3%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Asthenia<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Insomnia<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Leukorrhea<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2% of women<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Moniliasis<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Pruritus<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2%<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">Somnolence<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2%<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>*1733 males, 2108 females</paragraph>
                  <paragraph>The following laboratory value changes of possible clinical significance, irrespective of relationship to therapy with cefdinir, were seen during clinical trials conducted in the U.S.:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Laboratory Value Changes Observed with Cefdinir Capsules U.S. Trials in Adult and Adolescent </content>Patients (N=3841)<br/>
                  </paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" width="576.821">
                     <colgroup>
                        <col width="24.521558681116%"/>
                        <col width="51.9137652755361%"/>
                        <col width="23.5646760433479%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="5" valign="top">Incidence ≥1%<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">↑Urine leukocytes<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Urine protein <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Gamma-glutamyltransferase *<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">1%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↓Lymphocytes, ↑Lymphocytes <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">1%, 0.2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Microhematuria <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">1%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="18" valign="top">Incidence &lt; 1%<br/>but &gt; 0.1%<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">↑Glucose *<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.9%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Urine glucose <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.9%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑White blood cells, ↓White blood cells <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.9%,0.7%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Alanine aminotransferase (ALT) <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.7%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Eosinophils <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.7%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Urine specific gravity, ↓Urine specific gravity *<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.6%,0.2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↓Bicarbonate <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.6%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Phosphorus, ↓Phosphorus <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.6%, 0.3%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Aspartate aminotransferase (AST) <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.4%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Alkaline phosphatase <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.3%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Blood urea nitrogen (BUN) <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.3%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↓Hemoglobin <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.3%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Polymorphonuclear neutrophils (PMNs), ↓PMNs <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.3%,0.2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Bilirubin <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Lactate dehydrogenase *<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Platelets <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2%<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">↑Potassium *<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2%<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">↑Urine pH *<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0.2%<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>* N &lt; 3841 for these parameters</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="bold">Postmarketing Experience</content>
                        <br/>
                     </content>The following adverse experiences and altered laboratory tests, regardless of their relationship to cefdinir, have been reported during extensive postmarketing experience, beginning with approval in Japan in 1991: shock, anaphylaxis with rare cases of fatality, facial and laryngeal edema, feeling of suffocation, serum sickness-like reactions, conjunctivitis, stomatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, erythema nodosum, acute hepatitis, cholestasis, fulminant hepatitis, hepatic failure, jaundice, increased amylase, acute enterocolitis, bloody diarrhea, hemorrhagic colitis, melena, pseudomembranous colitis, pancytopenia, granulocytopenia, leukopenia, thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, acute respiratory failure, asthmatic attack, drug-induced pneumonia, eosinophilic pneumonia, idiopathic interstitial pneumonia, fever, acute renal failure, nephropathy, bleeding tendency, coagulation disorder, disseminated intravascular coagulation, upper GI bleed, peptic ulcer, ileus, loss of consciousness, allergic vasculitis, possible cefdinir-diclofenac interaction, cardiac failure, chest pain, myocardial infarction, hypertension, involuntary movements, and rhabdomyolysis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Cephalosporin Class Adverse Events</content>
                  </paragraph>
                  <paragraph>The following adverse events and altered laboratory tests have been reported for cephalosporin-class antibiotics in general:</paragraph>
                  <paragraph>Allergic reactions, anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, false-positive test for urinary glucose, neutropenia, pancytopenia, and agranulocytosis. Pseudomembranous colitis symptoms may begin during or after antibiotic treatment (see<content styleCode="italics"/>
                     <content styleCode="bold">WARNINGS</content>
                     <content styleCode="italics">).</content>
                  </paragraph>
                  <paragraph>Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see <content styleCode="bold">DOSAGE AND ADMINISTRATION </content>and <content styleCode="bold">OVERDOSAGE</content>). If seizures associated with drug therapy occur, the drug should be discontinued.</paragraph>
                  <paragraph> Anticonvulsant therapy can be given if clinically indicated.</paragraph>
               </text>
               <effectiveTime value="20231215"/>
            </section>
         </component>
         <component>
            <section ID="Section_9">
               <id root="981d3f30-57b9-42a7-841d-87794f701912"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Information on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600 mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other β-lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis removes cefdinir from the body. This may be useful in the event of a serious toxic reaction from overdosage, particularly if renal function is compromised.</paragraph>
               </text>
               <effectiveTime value="20220628"/>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="a1e1b416-ee60-49c3-82af-fc817e0eae53"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE &amp; ADMINISTRATION</title>
               <text>
                  <paragraph>(see <content styleCode="bold">INDICATIONS AND USAGE </content>for Indicated Pathogens)<br/> The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as b.i.d. dosing. Once-daily dosing has not been studied in pneumonia or skin infections; therefore, cefdinir capsules should be administered twice daily in these infections. Cefdinir capsules may be taken without regard to meals.<br/> Adults and Adolescents (Age 13 Years and Older)<br/>
                  </paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" width="469.0245">
                     <colgroup>
                        <col width="42.8611938182334%"/>
                        <col width="29.8029207429463%"/>
                        <col width="27.3358854388204%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Type of Infection<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Dosage<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Duration<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Community-Acquired Pneumonia<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">300 mg q12h <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">10 days<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Acute Exacerbations of Chronic<br/>Bronchitis<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">300 mg q12h<br/>or<br/>600 mg q24h<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">5 to 10 days<br/>10 days<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Acute Maxillary Sinusitis <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">300 mg q12h<br/>or<br/>600 mg q24h<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">10 days<br/>10 days<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Pharyngitis/Tonsillitis <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">300 mg q12h<br/>or<br/>600 mg q24h<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">5 to 10 days<br/>10 days<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">Uncomplicated Skin and Skin Structure Infections<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">300 mg q12h <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">10 days<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Patients with Renal Insufficiency</content>
                  </paragraph>
                  <paragraph>For adult patients with creatinine clearance &lt; 30 mL/min, the dose of cefdinir should be 300 mg given once daily.<br/>Creatinine clearance is difficult to measure in outpatients. However, the following formula may be used to estimate creatinine clearance (CL<sub>cr</sub> ) in adult patients. For estimates to be valid, serum creatinine levels should reflect steady-state levels of renal function.<br/>
                  </paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" width="547.827">
                     <colgroup>
                        <col width="34.4986647244477%"/>
                        <col width="19.9077445982034%"/>
                        <col width="45.5935906773489%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="2" valign="top">Males:<br/>
                           </td>
                           <td styleCode="Rrule" rowspan="2" valign="top">CL<sub>cr</sub> =<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">(weight) (140–age)<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">(72) (serum creatinine)<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">Females:<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">CL<sub>cr</sub> =<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">0 .8 5 x above value<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3" valign="top">where creatinine clearance is in mL/min, age is in years, weight is in kilograms, and serum creatinine is in mg/dL.<sup>1</sup>
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> The following formula may be used to estimate creatinine clearance in pediatric patients:<br/>
                  </paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" width="552.748">
                     <colgroup>
                        <col width="30.3296438883542%"/>
                        <col width="69.6703561116458%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="2" valign="top">CL<sub>cr</sub> = K x<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">body length or height<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">serum creatinine<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2" valign="top">where K=0.55 for pediatric patients older than 1 year<sup>2 </sup>and 0.45 for infants (up to 1 year).<sup>3</sup>
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> In the above equation, creatinine clearance is in mL/min/1.73 m<sup>2</sup>, body length or height is in centimeters, and serum creatinine is in mg/dL.</paragraph>
                  <paragraph> For pediatric patients with a creatinine clearance of &lt; 30 mL/min/1.73 m<sup>2</sup>, the dose of cefdinir should be 7 mg/kg (up to 300 mg) given once daily.<br/>
                     <content styleCode="bold">Patients on Hemodialysis<br/>
                     </content>Hemodialysis removes cefdinir from the body. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg/kg dose every other day. At the conclusion of each hemodialysis session, 300 mg (or 7 mg/kg) should be given. Subsequent doses (300 mg or 7 mg/kg) are then administered every other day.</paragraph>
               </text>
               <effectiveTime value="20231215"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="60c9ed79-fa23-4385-a805-a0a82a1fe7ea"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Cefdinir capsules, USP containing 300 mg cefdinir, having off white to light yellow colour granular powder filled in size “0” hard gelatin capsules, blue opaque cap imprinted “A041” with black ink and blue opaque body imprinted “300” with black ink and are supplied as follows:</paragraph>
                  <list listType="unordered">
                     <item>NDC 63629-5101-1: 10 CAPSULEs in a BOTTLE</item>
                  </list>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</paragraph>
                  <paragraph>Repackaged/Relabeled by:<br/>Bryant Ranch Prepack, Inc.<br/>Burbank, CA 91504</paragraph>
               </text>
               <effectiveTime value="20250408"/>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="562fa05f-f034-473e-ba35-ce543590216c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>CLINICAL STUDIES</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Community-Acquired Bacterial Pneumonia</content>
                  </paragraph>
                  <paragraph>In a controlled, double-blind study in adults and adolescents conducted in the U.S., cefdinir b.i.d. was compared with cefaclor 500 mg t.i.d.. Using strict evaluability and microbiologic/clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:</paragraph>
                  <br/>
                  <paragraph> U.S. Community-Acquired Pneumonia Study Cefdinir vs Cefaclor</paragraph>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0" width="586.53">
                     <colgroup>
                        <col width="27.18820861678%"/>
                        <col width="23.8888888888889%"/>
                        <col width="24.8979591836735%"/>
                        <col width="24.0249433106576%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <content styleCode="bold">Cefdinir b.i.d.</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <content styleCode="bold">Cefaclort.i.d</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <content styleCode="bold">Outcome</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Clinical Cure Rates</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">150 /187 (80%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">147/186 (79%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Cefdinir equivalent to control<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Eradication Rates</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">Overall<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">177/195 (91%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">184/200 (92%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Cefdinir equivalent to control<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">S. pneumoniae</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">31/31(100%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">35/35 (100%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">H. influenzae</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">55/65 (85%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">60/72 (83%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">M. catarrhalis</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">10/10 (100%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">11/11 (100%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">H. parainfluenzae</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">81/89 (91%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">78/82 (95%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>  In a second controlled, investigator-blind study in adults and adolescents conducted primarily in Europe, cefdinir b.i.d. was compared with amoxicillin/clavulanate 500/125 mg t.i.d. Using strict evaluability and clinical response criteria 6 to 14 days posttherapy, the following clinical cure rates, presumptive microbiologic eradication rates, and statistical outcomes were obtained:<br/>
                     <content styleCode="bold">European Community-Acquired Pneumonia Study Cefdinir vs Amoxicillin/Clavulanate<br/>
                     </content>
                  </paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" width="585.865">
                     <colgroup>
                        <col width="27.1736662883087%"/>
                        <col width="23.9046538024972%"/>
                        <col width="24.8921679909194%"/>
                        <col width="24.0295119182747%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <content styleCode="bold">Cefdinir b.i.d.</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <content styleCode="bold">Amoxicillin/</content>
                              <br/>
                              <content styleCode="bold">Clavulanate t.i.d.</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <content styleCode="bold">Outcome</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Clinical Cure Rates</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">83/104 (80%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">86/97 (89%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Cefdinir not equivalent to control<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Eradication Rates</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="middle">Overall<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">85/96 (89%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">84/90 (93%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">Cefdinir equivalent to control<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">S. pneumoniae</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">42/44 (95%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">43/44 (98%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">H. influenzae</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">26/35 (74%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">21/26 (81%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">M. catarrhalis</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">  6/6 (100%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">8/8 (100%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="italics">H. parainfluenzae</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">11/11(100%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="middle">12/12(100%)<br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Streptococcal Pharyngitis /Tonsillitis</content>
                  </paragraph>
                  <paragraph>In four controlled studies conducted in the United States, cefdinir was compared with 10 days of penicillin in adult, adolescent, and pediatric patients. Two studies (one in adults and adolescents, the other in pediatric patients) compared 10 days of cefdinir q.d. or b.i.d. to penicillin 250 mg or 10 mg/kg q.i.d. Using strict evaluability and microbiologic/clinical response criteria 5 to 10 days posttherapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Pharyngitis /Tonsillitis Studies Cefdinir (10 days) vs Penicillin (10 days)</content>
                  </paragraph>
                  <table cellspacing="0" cellpadding="0" border="0" width="915.04">
                     <colgroup>
                        <col width="20.9302325581395%"/>
                        <col width="22.8197674418605%"/>
                        <col width="14.6802325581395%"/>
                        <col width="12.2093023255814%"/>
                        <col width="12.2093023255814%"/>
                        <col width="17.1511627906977%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" valign="top">
                              <content styleCode="bold">Study</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="top">
                              <content styleCode="bold">Efficacy</content>
                              <br/>
                              <content styleCode="bold">          Parameter</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <content styleCode="bold">C</content>
                              <content styleCode="bold">e</content>
                              <content styleCode="bold">f</content>
                              <content styleCode="bold">d</content>
                              <content styleCode="bold">i</content>
                              <content styleCode="bold">n</content>
                              <content styleCode="bold">i</content>
                              <content styleCode="bold">r q.d.</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="top">
                              <content styleCode="bold">C</content>
                              <content styleCode="bold">e</content>
                              <content styleCode="bold">f</content>
                              <content styleCode="bold">d</content>
                              <content styleCode="bold">i</content>
                              <content styleCode="bold">n</content>
                              <content styleCode="bold">i</content>
                              <content styleCode="bold">r b.i.d.</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="top">
                              <content styleCode="bold">P</content>
                              <content styleCode="bold">e</content>
                              <content styleCode="bold">n</content>
                              <content styleCode="bold">i</content>
                              <content styleCode="bold">c</content>
                              <content styleCode="bold">illi</content>
                              <content styleCode="bold">n q.i.d.</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="top">
                              <content styleCode="bold">O</content>
                              <content styleCode="bold">u</content>
                              <content styleCode="bold">t</content>
                              <content styleCode="bold">c</content>
                              <content styleCode="bold">o</content>
                              <content styleCode="bold">m</content>
                              <content styleCode="bold">e</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="2" valign="top">Adults/ Adolescents<br/>
                           </td>
                           <td styleCode="Rrule" rowspan="2" valign="top">Eradication of S. pyogenes<br/>Clinical Cure Rates<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">192/210 <br/>(91%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">199 /217 (92%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">181/217<br/>(83%)<br/>
                           </td>
                           <td styleCode="Rrule" align="left" valign="middle">Cefdinir superior to control<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="middle">199/210 <br/>(95%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">209 /217<br/>(96%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">193/217<br/>(89%)<br/>
                           </td>
                           <td styleCode="Rrule" align="left" valign="middle">Cefdinir superior to control<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="2" valign="top">Pediatric Patients<br/>
                           </td>
                           <td styleCode="Rrule" rowspan="2" valign="top">Eradication of S.<br/>pyogenes <br/>Clinical Cure Rates<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">215/228<br/>(94%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">214/227<br/>(94%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">159/227<br/>(70%)<br/>
                           </td>
                           <td styleCode="Rrule" align="left" valign="middle">Cefdinir superior to control<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" align="center" valign="middle">222/228<br/>(97%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">218/227<br/>(96%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">196/227<br/>(86%)<br/>
                           </td>
                           <td styleCode="Rrule" align="left" valign="middle">Cefdinir superior to control<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Two studies (one in adults and adolescents, the other in pediatric patients) compared 5 days of cefdinir b.i.d. to 10 days of penicillin 250 mg or 10 mg/kg q.i.d.. Using strict evaluability and microbiologic/clinical response criteria 4 to 10 days post therapy, the following clinical cure rates, microbiologic eradication rates, and statistical outcomes were obtained:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pharyngitis /Tonsillitis Studies Cefdinir (5 days ) vs Penicillin (10 days )<br/>
                     </content>
                  </paragraph>
                  <br/>
                  <table cellspacing="0" cellpadding="0" border="0" width="663">
                     <colgroup>
                        <col width="21.562123039807%"/>
                        <col width="20.2653799758745%"/>
                        <col width="18.8078005629272%"/>
                        <col width="18.9585846401287%"/>
                        <col width="20.4061117812626%"/>
                     </colgroup>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="middle">
                              <content styleCode="bold">Study</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">
                              <content styleCode="bold">Efficacy</content>
                              <br/>
                              <content styleCode="bold">Parameter</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">
                              <content styleCode="bold">Cefdinir b.i.d.</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">
                              <content styleCode="bold">Penicillin q.i.d.</content>
                              <br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">
                              <content styleCode="bold">Outcome</content>
                              <br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="2" align="justify" valign="middle">Adults/ Adolescents<br/>
                           </td>
                           <td styleCode="Rrule" rowspan="2" align="center" valign="middle">Eradication of<content styleCode="italics"/>
                              <br/>
                              <content styleCode="italics"> S. pyogenes</content>
                              <br/>Clinical Cure Rates<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">193/218 (89%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">176/214 (82%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">Cefdinir equivalent to control<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" align="center" valign="middle">194/218 (89%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">181/214 (85%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">Cefdinir equivalent to control<br/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="2" align="justify" valign="middle">Pediatric Patients<br/>
                           </td>
                           <td styleCode="Rrule" rowspan="2" align="center" valign="middle">Eradication of<content styleCode="italics"> S. pyogenes</content>
                              <br/>Clinical Cure Rates<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">176/196 (90%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">135/193 (70%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">Cefdinir superior to control<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" align="center" valign="middle">179/196 (91%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">173/193 (90%)<br/>
                           </td>
                           <td styleCode="Rrule" align="center" valign="middle">Cefdinir equivalent to control<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
               </text>
               <effectiveTime value="20231215"/>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="aabf2d5d-7e09-423b-a48b-ffd0d25c5234"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>REFERENCES</title>
               <text>
                  <br/>
                  <list listType="ordered" styleCode="Arabic">
                     <item>Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.</item>
                     <item>Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-63. </item>
                     <item>Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatrics 1984;104:849-54. </item>
                  </list>
                  <br/>
                  <paragraph>All brand names listed are the registered trademarks of their respective owners and are not trademarks of  Alkem Laboratories Ltd.</paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>Alkem Laboratories Ltd.,</paragraph>
                  <paragraph>INDIA.</paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>Ascend Laboratories, LLC</paragraph>
                  <paragraph>339 Jefferson Road,</paragraph>
                  <paragraph> Parsippany, NJ 07054</paragraph>
                  <paragraph>Revised: June, 2023</paragraph>
                  <br/>
                  <paragraph>PT2808-02</paragraph>
               </text>
               <effectiveTime value="20231215"/>
            </section>
         </component>
         <component>
            <section>
               <id root="bab5b815-0be4-45ee-b345-41209d6011df"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Cefdinir 300mg Capsule</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="mm63629"/>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <observationMedia ID="mm63629">
                     <text>Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl636295101.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>